MarketCap
Facebook
X
TelegramQuarterly report 2022-Q1
added 12-16-2023
Cerner Corporation Revenue 2011-2026 | CERN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Cerner Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.76 B | 5.51 B | 5.69 B | 5.37 B | 5.14 B | 4.43 B | 3.4 B | - | 2.91 B | 2.67 B | 1.85 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.76 B | 1.85 B | 4.27 B |
Quarterly Revenue Cerner Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1.43 B | - | 1.47 B | 1.46 B | 1.39 B | 1.4 B | 1.37 B | 1.33 B | 1.41 B | 1.44 B | 1.43 B | 1.43 B | 1.39 B | 1.37 B | 1.34 B | 1.37 B | 1.29 B | 1.31 B | 1.28 B | 1.29 B | 1.26 B | 1.26 B | 1.18 B | 1.22 B | 1.14 B | 926 M | 1.13 B | 1.13 B | 996 M | - | 840 M | 852 M | 785 M | 795 M | 728 M | 708 M | 680 M | 710 M | 676 M | 637 M | 641 M | 616 M | 572 M | 524 M | 492 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.47 B | 492 M | 1.09 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M |  USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
American Well Corporation
AMWL
|
249 M | $ 5.55 | -1.42 % | $ 89.1 M | USA |
 |
Computer Programs and Systems
CPSI
|
339 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
Schrödinger
SDGR
|
256 M | $ 11.52 | 1.05 % | $ 846 M | USA |
 |
Phreesia
PHR
|
356 M | $ 11.52 | 2.49 % | $ 629 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Teladoc Health
TDOC
|
2.53 B | $ 5.52 | -0.9 % | $ 973 M | USA |
 |
Evolent Health
EVH
|
382 M | $ 2.3 | 1.55 % | $ 216 M | USA |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
10x Genomics
TXG
|
619 M | $ 20.97 | 0.29 % | $ 2.46 B | USA |
 |
1Life Healthcare
ONEM
|
623 M | - | - | $ 3.37 B | USA |
 |
MTBC
MTBC
|
120 M | - | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
263 M | - | - | $ 2.33 B | USA |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.06 | -0.24 % | $ 795 M | USA |
 |
SCWorx Corp.
WORX
|
2.99 M | $ 0.14 | 7.38 % | $ 204 K | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
HealthStream
HSTM
|
292 M | $ 21.24 | 0.05 % | $ 645 M | USA |
 |
Akerna Corp.
KERN
|
20.5 M | - | - | $ 161 M | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 1.78 | -1.11 % | $ 9.27 M |  China |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
Health Catalyst
HCAT
|
311 M | $ 1.09 | -0.91 % | $ 76.2 M | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
HealthEquity
HQY
|
1.31 B | $ 83.31 | 1.01 % | $ 7.18 B | USA |
 |
Omnicell
OMCL
|
1.11 B | $ 35.35 | 1.17 % | $ 1.63 B | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 7.0 | -2.51 % | $ 120 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
Progyny
PGNY
|
298 M | $ 17.91 | 0.9 % | $ 1.54 B | USA |
 |
So-Young International
SY
|
-1.52 M | $ 2.88 | -9.87 % | $ 229 M | China |
 |
Veeva Systems
VEEV
|
3.2 B | $ 180.16 | 1.17 % | $ 29.5 B | USA |